

David Jiménez, Fccp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4584203/publications.pdf>

Version: 2024-02-01

248
papers

23,289
citations

38742

50
h-index

8396

147
g-index

267
all docs

267
docs citations

267
times ranked

18133
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2016, 149, 315-352.	0.8	4,060
2	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	2.2	2,591
3	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	2.2	2,426
4	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.8	2,392
5	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 370, 1402-1411.	27.0	1,221
6	Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary Embolism. <i>Archives of Internal Medicine</i> , 2010, 170, 1383.	3.8	959
7	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Respiratory Journal</i> , 2019, 54, 1901647.	6.7	806
8	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. <i>Chest</i> , 2020, 158, 1143-1163.	0.8	531
9	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	7.4	515
10	Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019. <i>Chest</i> , 2021, 159, 1182-1196.	0.8	361
11	Trends in the Management and Outcomes of Acute Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 162-170.	2.8	271
12	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1536-1544.	2.8	258
13	Predictive Value of the High-Sensitivity Troponin T Assay and the Simplified Pulmonary Embolism Severity Index in Hemodynamically Stable Patients With Acute Pulmonary Embolism. <i>Circulation</i> , 2011, 124, 2716-2724.	1.6	219
14	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.4	206
15	Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. <i>European Respiratory Journal</i> , 2014, 44, 694-703.	6.7	186
16	Troponin-Based Risk Stratification of Patients With Acute Nonmassive Pulmonary Embolism. <i>Chest</i> , 2009, 136, 974-982.	0.8	179
17	Prognostic Models for Selecting Patients With Acute Pulmonary Embolism for Initial Outpatient Therapy. <i>Chest</i> , 2007, 132, 24-30.	0.8	168
18	Survival Effects of Inferior Vena Cava Filter in Patients With Acute Symptomatic Venous Thromboembolism and a Significant Bleeding Risk. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1675-1683.	2.8	167

#	ARTICLE	IF	CITATIONS
19	Derivation and Validation of Multimarker Prognostication for Normotensive Patients with Acute Symptomatic Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 718-726.	5.6	164
20	Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). <i>Thrombosis and Haemostasis</i> , 2018, 118, 214-224.	3.4	160
21	Prognostic Significance of Deep Vein Thrombosis in Patients Presenting with Acute Symptomatic Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 983-991.	5.6	154
22	Weekend Versus Weekday Admission and Mortality After Acute Pulmonary Embolism. <i>Circulation</i> , 2009, 119, 962-968.	1.6	150
23	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	2.8	150
24	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. <i>Lancet Oncology</i> , The, 2022, 23, e334-e347.	10.7	138
25	Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. <i>European Respiratory Journal</i> , 2014, 43, 1669-1677.	6.7	121
26	Incidence of Air Travel-Related Pulmonary Embolism at the Madrid-Barajas Airport. <i>Archives of Internal Medicine</i> , 2003, 163, 2766.	3.8	120
27	Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. <i>Thorax</i> , 2011, 66, 75-81.	5.6	115
28	Home treatment in pulmonary embolism. <i>Thrombosis Research</i> , 2010, 126, e1-e5.	1.7	111
29	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	2.2	106
30	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 33-42.	10.7	100
31	Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 110, 834-843.	3.4	94
32	Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. <i>European Respiratory Journal</i> , 2014, 44, 942-950.	6.7	88
33	Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2015, 148, 211-218.	0.8	85
34	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT. <i>Chest</i> , 2016, 149, 192-200.	0.8	76
35	A Strategy Combining Imaging and Laboratory Biomarkers in Comparison With a Simplified Clinical Score for Risk Stratification of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2012, 141, 916-922.	0.8	75
36	Risk stratification of normotensive patients with acute symptomatic pulmonary embolism. <i>British Journal of Haematology</i> , 2010, 151, 415-424.	2.5	72

#	ARTICLE	IF	CITATIONS
37	Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar. Archivos De Bronconeumología, 2013, 49, 534-547.	0.8	70
38	Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. JAMA - Journal of the American Medical Association, 2019, 322, 574.	7.4	69
39	Pulmonary Embolism in Patients with Chronic Obstructive Pulmonary Disease or Congestive Heart Failure. American Journal of Medicine, 2006, 119, 851-858.	1.5	68
40	Prognostic Significance of Right Heart Thrombi in Patients With Acute Symptomatic Pulmonary Embolism. Chest, 2017, 151, 409-416.	0.8	65
41	Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. European Heart Journal, 2021, 42, 3146-3157.	2.2	64
42	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thrombosis Research, 2020, 196, 382-394.	1.7	62
43	Prognostic significance of multidetector CT in normotensive patients with pulmonary embolism: results of the protect study. Thorax, 2014, 69, 109-115.	5.6	61
44	A Clinical Prognostic Model for the Identification of Low-Risk Patients With Acute Symptomatic Pulmonary Embolism and Active Cancer. Chest, 2013, 143, 138-145.	0.8	58
45	Right heart thrombi in pulmonary embolism. European Respiratory Journal, 2016, 48, 1377-1385.	6.7	58
46	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.8	58
47	Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate. Thorax, 2015, 70, 333-338.	5.6	55
48	Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. European Heart Journal, 2018, 39, 4186-4195.	2.2	55
49	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis and Haemostasis, 2022, 122, 131-141.	3.4	55
50	Short-term clinical outcome after acute symptomatic pulmonary embolism. Thrombosis and Haemostasis, 2008, 100, 937-942.	3.4	54
51	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2017, 151, 564-571.	0.8	51
52	A comparison of the original and simplified Pulmonary Embolism Severity Index. Thrombosis and Haemostasis, 2011, 106, 423-428.	3.4	50
53	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thrombosis and Haemostasis, 2021, 121, 982-991.	3.4	50
54	Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Current Opinion in Pulmonary Medicine, 2008, 14, 414-421.	2.6	47

#	ARTICLE	IF	CITATIONS
55	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	2.9	46
56	Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism. <i>Thrombosis Research</i> , 2011, 127, 303-308.	1.7	45
57	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. <i>American Journal of Medicine</i> , 2017, 130, 588-595.	1.5	45
58	Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>Clinical Research in Cardiology</i> , 2019, 108, 772-778.	3.3	44
59	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 408-411.	2.8	44
60	Bleeding risk in hospitalized patients with COVID-19 receiving intermediate or therapeutic doses of thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1981-1989.	3.8	42
61	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	2.8	42
62	Epidemiology, patterns of care and mortality for patients with hemodynamically unstable acute symptomatic pulmonary embolism. <i>International Journal of Cardiology</i> , 2018, 269, 327-333.	1.7	41
63	Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. <i>BMJ: British Medical Journal</i> , 2019, 366, 14416.	2.3	41
64	Incidence of Symptomatic and Asymptomatic Chronic Thromboembolic Pulmonary Hypertension. <i>Archivos De Bronconeumología</i> , 2010, 46, 628-633.	0.8	40
65	Interobserver reliability of echocardiography for prognostication of normotensive patients with pulmonary embolism. <i>Cardiovascular Ultrasound</i> , 2014, 12, 29.	1.6	40
66	Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2021, 42, 3190-3199.	2.2	40
67	Risk stratification of patients with acute symptomatic pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2016, 11, 11-18.	2.0	39
68	Sex differences in the characteristics and short-term prognosis of patients presenting with acute symptomatic pulmonary embolism. <i>PLoS ONE</i> , 2017, 12, e0187648.	2.5	39
69	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016, 116, 191-197.	3.4	38
70	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. <i>Quality of Life Research</i> , 2019, 28, 2111-2124.	3.1	38
71	Meta-Analysis of Prevalence and Short-Term Prognosis of Hemodynamically Unstable Patients With Symptomatic Acute Pulmonary Embolism. <i>American Journal of Cardiology</i> , 2019, 123, 684-689.	1.6	36
72	Prognostic value of right ventricular dilatation in patients with low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2017, 50, 1701611.	6.7	35

#	ARTICLE	IF	CITATIONS
73	A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism. <i>Thrombosis Research</i> , 2018, 165, 107-111.	1.7	35
74	Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-â€“High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 857-866.	3.4	35
75	Changes in PESI scores predict mortality in intermediate-risk patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2013, 41, 354-359.	6.7	34
76	Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism. <i>European Respiratory Journal</i> , 2015, 45, 1323-1331.	6.7	34
77	Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 351-361.	2.7	34
78	Comparison of clinical scores for identification of patients with pulmonary embolism at intermediate-â€“high risk of adverse clinical outcome: the prognostic role of plasma lactate. <i>Internal and Emergency Medicine</i> , 2017, 12, 657-665.	2.0	33
79	Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: systematic review and network meta-analysis. <i>Thorax</i> , 2018, 73, 464-471.	5.6	33
80	Management appropriateness and outcomes of patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2018, 51, 1800445.	6.7	33
81	Prognostic significance of multidetector computed tomography in normotensive patients with pulmonary embolism: rationale, methodology and reproducibility for the PROTECT study. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 187-192.	2.1	31
82	Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2440-2448.	2.9	31
83	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009042.	3.7	31
84	Obstructive sleep apnoea and venous thromboembolism: pathophysiological links and clinical implications. <i>European Respiratory Journal</i> , 2019, 53, 1800893.	6.7	31
85	Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. <i>Thrombosis and Haemostasis</i> , 2016, 115, 827-834.	3.4	30
86	Assessment of right ventricular function in acute pulmonary embolism. <i>American Heart Journal</i> , 2017, 185, 123-129.	2.7	30
87	Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study. <i>European Respiratory Journal</i> , 2018, 51, 1702037.	6.7	30
88	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-â€“VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	3.8	30
89	Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. <i>European Respiratory Journal</i> , 2020, 56, 2002336.	6.7	30
90	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. <i>Thrombosis Research</i> , 2018, 170, 181-191.	1.7	29

#	ARTICLE	IF	CITATIONS
91	Multidetector computed tomographic pulmonary angiography in patients with a high clinical probability of pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 114-120.	3.8	28
92	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1277.	7.4	28
93	Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy. <i>Annals of the American Thoracic Society</i> , 2015, 12, 150626095350002.	3.2	27
94	Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-Treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. <i>Academic Emergency Medicine</i> , 2016, 23, 144-150.	1.8	25
95	The Prognostic Value of Renal Function in Acute Pulmonary Embolism—A Multi-Centre Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 140-148.	3.4	24
96	Apixaban: an Oral Direct Factor-Xa Inhibitor. <i>Advances in Therapy</i> , 2012, 29, 187-201.	2.9	23
97	DVT Management and Outcome Trends, 2001 to 2014. <i>Chest</i> , 2016, 150, 374-383.	0.8	23
98	Intermediate-High Risk Pulmonary Embolism. <i>TH Open</i> , 2019, 03, e356-e363.	1.4	23
99	Catheter-directed aspiration thrombectomy and low-dose thrombolysis for patients with acute unstable pulmonary embolism: Prospective outcomes from a PE registry. <i>International Journal of Cardiology</i> , 2019, 287, 106-110.	1.7	22
100	Association of anaemia and mortality in patients with acute pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2009, 102, 153-158.	3.4	21
101	Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. <i>European Respiratory Journal</i> , 2016, 48, 1360-1368.	6.7	21
102	Clinical Prognosis of Nonmassive Central and Noncentral Pulmonary Embolism. <i>Chest</i> , 2017, 151, 829-837.	0.8	21
103	Identification of Reduced Circulating Haptoglobin Concentration as a Biomarker of the Severity of Pulmonary Embolism: A Nontargeted Proteomic Study. <i>PLoS ONE</i> , 2014, 9, e100902.	2.5	19
104	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. <i>Viruses</i> , 2022, 14, 178.	3.3	18
105	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 57, 2002368.	6.7	17
106	Controversies in the Management of Life-Threatening Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 835-841.	2.1	16
107	Type 2 diabetes is associated with a higher incidence of hospitalization for pulmonary embolism in Spain: Analysis of hospital discharge data during 2004–2013. <i>Respirology</i> , 2016, 21, 1277-1284.	2.3	16
108	Accuracy and Interobserver Reliability of the Simplified Pulmonary Embolism Severity Index Versus the Hestia Criteria for Patients With Pulmonary Embolism. <i>Academic Emergency Medicine</i> , 2019, 26, 394-401.	1.8	16

#	ARTICLE	IF	CITATIONS
109	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. PLoS ONE, 2018, 13, e0194673.	2.5	16
110	Prognostic importance of anaemia in patients with acute pulmonary embolism. Thrombosis and Haemostasis, 2011, 106, 289-295.	3.4	15
111	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous thromboembolism in Europe (ETNA-VTE-Europe) study. Thrombosis Journal, 2018, 16, 9.	2.1	15
112	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology, 2022, 7, 747.	6.1	15
113	Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. JAMA Cardiology, 2022, 7, 857.	6.1	15
114	Chronic Obstructive Pulmonary Disease in Patients With Acute Symptomatic Pulmonary Embolism. Archivos De Bronconeumología, 2009, 45, 286-290.	0.8	14
115	Point: Should Systemic Lytic Therapy Be Used for Submassive Pulmonary Embolism? Yes. Chest, 2013, 143, 296-299.	0.8	14
116	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. Chest, 2022, 161, 524-534.	0.8	14
117	Impact of obstructive sleep apnea on cardiovascular outcomes in patients with acute symptomatic pulmonary embolism: Rationale and methodology for the POPE study. Clinical Cardiology, 2017, 40, 1182-1188.	1.8	13
118	Risk stratification of acute pulmonary embolism based on clinical parameters, H-FABP and multidetector CT. International Journal of Cardiology, 2018, 265, 223-228.	1.7	13
119	Pulmonary embolism severity assessment and prognostication. Thrombosis Research, 2018, 163, 246-251.	1.7	13
120	Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. European Respiratory Journal, 2019, 53, 1801677.	6.7	13
121	Systolic blood pressure and mortality in acute symptomatic pulmonary embolism. International Journal of Cardiology, 2020, 302, 157-163.	1.7	13
122	Renal dysfunction improves risk stratification and may call for a change in the management of intermediate- and high-risk acute pulmonary embolism: results from a multicenter cohort study with external validation. Critical Care, 2021, 25, 57.	5.8	13
123	Validación de 2 escalas clínicas pronósticas en pacientes con tromboembolia pulmonar aguda sintomática. Archivos De Bronconeumología, 2013, 49, 427-431.	0.8	12
124	Assessment of coexisting deep vein thrombosis for risk stratification of acute pulmonary embolism. Thrombosis Research, 2018, 164, 40-44.	1.7	12
125	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2019, 45, 793-801.	2.7	12
126	Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 408-416.	3.8	12

#	ARTICLE	IF	CITATIONS
127	Consenso multidisciplinar para el manejo de la tromboembolia de pulmón. Archivos De Bronconeumología, 2022, 58, 246-254.	0.8	12
128	Prognostic Impact of Obstructive Sleep Apnea in Patients Presenting with Acute Symptomatic Pulmonary Embolism. Thrombosis and Haemostasis, 2021, 121, 808-815.	3.4	12
129	Validation of Two Clinical Prognostic Models in Patients With Acute Symptomatic Pulmonary Embolism. Archivos De Bronconeumología, 2013, 49, 427-431.	0.8	11
130	Pulmonary embolism: current and new treatment options. Current Medical Research and Opinion, 2014, 30, 1975-1989.	1.9	11
131	Pulmonary embolism, acute coronary syndrome and ischemic stroke in the Spanish National Discharge Database. European Journal of Internal Medicine, 2016, 28, 65-69.	2.2	11
132	Risk Stratification for Proven Acute Pulmonary Embolism: What Information Is Needed?. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 011-017.	2.1	11
133	Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism. European Respiratory Journal, 2022, 59, 2100412.	6.7	11
134	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematology, 2021, 8, e627-e636.	4.6	11
135	Short-term clinical outcome after acute symptomatic pulmonary embolism. Thrombosis and Haemostasis, 2008, 100, 937-42.	3.4	11
136	Catheter-Based Approaches for the Treatment of Acute Pulmonary Embolism. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 073-083.	2.1	10
137	Evaluación clínica frente a escalas estandarizadas para el pronóstico de los pacientes con tromboembolia pulmonar aguda sintomática. Medicina Clínica, 2018, 151, 136-140.	0.6	10
138	Systematic review of efficacy and safety of retrievable inferior vena caval filters. Thrombosis Research, 2018, 165, 79-82.	1.7	10
139	Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days. American Heart Journal, 2018, 206, 1-10.	2.7	10
140	Outcomes after Vena Cava Filter Use in Patients with Cancer-Associated Venous Thromboembolism and Contraindications to Anticoagulation. Thrombosis and Haemostasis, 2020, 120, 1035-1044.	3.4	10
141	Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 168-178.	2.3	10
142	National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism. Archivos De Bronconeumología, 2013, 49, 534-547.	0.8	9
143	Reply. Journal of the American College of Cardiology, 2014, 64, 955-956.	2.8	9
144	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. Thrombosis and Haemostasis, 2017, 117, 2425-2434.	3.4	9

#	ARTICLE	IF	CITATIONS
145	Pulmonary Embolism Response Teams: Pursuing Excellence in the Care for Venous Thromboembolism. Archives of Medical Research, 2019, 50, 257-258.	3.3	9
146	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. Clinical Cardiology, 2019, 42, 346-351.	1.8	9
147	Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. Internal and Emergency Medicine, 2019, 14, 1101-1112.	2.0	9
148	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. JAMA Internal Medicine, 2019, 179, 263.	5.1	9
149	Clinical characteristics and 3-month outcomes in cancer patients with incidental <i>versus</i> clinically suspected and confirmed pulmonary embolism. European Respiratory Journal, 2021, 58, 2002723.	6.7	9
150	Aggressive Treatment of Intermediate-Risk Patients with Acute Symptomatic Pulmonary Embolism. Clinics in Chest Medicine, 2018, 39, 569-581.	2.1	8
151	Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism. Circulation: Cardiovascular Imaging, 2020, 13, e010651.	2.6	8
152	The effect of COPD on the incidence and mortality of hospitalized patients with pulmonary embolism: A nationwide population-based study (2016-2018). European Journal of Internal Medicine, 2021, 84, 18-23.	2.2	8
153	Systematic testing for venous thromboembolism in hospitalized patients with COVID-19 and raised D-dimer levels. Thrombosis Update, 2021, 2, 100029.	0.9	8
154	Risk assessment and management of high and intermediate risk pulmonary embolism. Presse Medicale, 2015, 44, e401-e408.	1.9	7
155	Prognostic Scores for Acute Pulmonary Embolism. Seminars in Thrombosis and Hemostasis, 2017, 43, 486-492.	2.7	7
156	Comparison of All-Cause Mortality Following VTE Treatment Between Propensity Score-Adjusted Observational Studies and Matched Randomized Controlled Trials. Chest, 2019, 155, 689-698.	0.8	7
157	Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 769.	2.3	7
158	Changing Trends in Hospital Admissions for Pulmonary Embolism in Spain from 2001 to 2018. Journal of Clinical Medicine, 2020, 9, 3221.	2.4	7
159	Clinical conundrum: concomitant high-risk pulmonary embolism and acute ischemic stroke. Emergency Radiology, 2020, 27, 433-439.	1.8	7
160	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 489-495.	1.7	6
161	Success in Optional Vena Cava Filter Retrieval. An Analysis of 246 Patients. Archivos De Bronconeumologia, 2018, 54, 371-377.	0.8	6
162	Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi. European Respiratory Journal, 2020, 56, 2000538.	6.7	6

#	ARTICLE	IF	CITATIONS
163	Prognostic significance of computed tomography-assessed right ventricular enlargement in low-risk patients with pulmonary embolism: Systematic review and meta-analysis. <i>Thrombosis Research</i> , 2021, 197, 48-55.	1.7	6
164	Risk stratification for predicting recurrent venous thromboembolism after discontinuation of anticoagulation: a post hoc analysis of a French prospective multicentre study. <i>European Respiratory Journal</i> , 2022, 60, 2103002.	6.7	6
165	COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No. <i>Chest</i> , 2022, 161, 1448-1451.	0.8	6
166	Pulmonary Embolism in Patients with COVID-19: Comparison between Different Care Settings. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 034-046.	2.7	6
167	Performance of Early Prognostic Assessment Independently Predicts the Outcomes in Patients with Acute Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , 2018, 47, 798-800.	3.4	5
168	Diclofenac for reversal of right ventricular dysfunction in acute normotensive pulmonary embolism: A pilot study. <i>Thrombosis Research</i> , 2018, 162, 1-6.	1.7	5
169	Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years. <i>Scientific Reports</i> , 2019, 9, 20064.	3.3	5
170	Atrial fibrillation in the course of pulmonary embolism: just a little smoke, or fuel to the fire?. <i>Journal of Internal Medicine</i> , 2020, 287, 114-116.	6.0	5
171	Necesidad de una ecocardiografía transtorácica en pacientes con tromboembolia de pulmón de riesgo bajo: revisión sistemática y metanálisis. <i>Archivos De Bronconeumología</i> , 2020, 56, 306-313.	0.8	5
172	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , 2020, 82, 48-55.	2.2	5
173	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. <i>Thrombosis Research</i> , 2020, 196, 297-304.	1.7	5
174	Need for Transthoracic Echocardiogram in Patients with Low-Risk Pulmonary Thromboembolism: A Systematic Review and Meta-Analysis. <i>Archivos De Bronconeumología</i> , 2020, 56, 306-313.	0.8	5
175	Clinical significance and management of right heart thrombi: more questions than answers. <i>European Respiratory Journal</i> , 2016, 47, 702-703.	6.7	4
176	Actualización del Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia de pulmón. <i>Archivos De Bronconeumología</i> , 2016, 52, 61-62.	0.8	4
177	Éxito en la recuperación de filtro de vena cava inferior opcional: Análisis de 246 pacientes. <i>Archivos De Bronconeumología</i> , 2018, 54, 371-377.	0.8	4
178	Pulmonary embolism in Europe remains a cause of concern despite declining deaths. <i>Lancet Respiratory Medicine</i> , 2020, 8, 222-224.	10.7	4
179	Impact and Role of Pulmonary Embolism Response Teams in Venous Thromboembolism Associated with Covid-19. <i>Journal of Investigative Medicine</i> , 2021, 69, 1153-1155.	1.6	4
180	RIETE Registry: Past, Present and Future. <i>Archivos De Bronconeumología</i> , 2022, 58, 205-207.	0.8	4

#	ARTICLE	IF	CITATIONS
181	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021, 10, e021467.	3.7	4
182	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. <i>Viruses</i> , 2021, 13, 2128.	3.3	4
183	[Translated article] Multidisciplinary consensus for the management of pulmonary thromboembolism. <i>Archivos De Bronconeumología</i> , 2022, 58, T246-T254.	0.8	4
184	Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1839-1851.	3.8	4
185	Untreated obstructive sleep apnea and cardiovascular outcomes in patients with acute symptomatic pulmonary embolism. <i>Thrombosis Research</i> , 2022, 214, 87-92.	1.7	4
186	Clinical Characteristics and Prognosis of Pulmonary Embolism Caused by Economy Class Syndrome. <i>Archivos De Bronconeumología</i> , 2017, 53, 495-500.	0.8	3
187	Outpatient therapy for acute symptomatic pulmonary embolism diagnosed in the emergency department: Time to improve the evidence base. <i>Thrombosis Research</i> , 2018, 161, 117-118.	1.7	3
188	Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism. <i>TH Open</i> , 2018, 02, e428-e436.	1.4	3
189	Risk adapted management of acute pulmonary embolism in women. <i>Thrombosis Research</i> , 2019, 181, S29-S32.	1.7	3
190	Outcome of patients with acute symptomatic pulmonary embolism and psychiatric disorders. <i>Thrombosis Research</i> , 2020, 193, 90-97.	1.7	3
191	The significance of heart failure in hospitalised patients with pulmonary embolism. A gender-specific analysis. <i>International Journal of Clinical Practice</i> , 2021, 75, e14558.	1.7	3
192	Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 58-66.	2.1	3
193	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	1.8	3
194	Sex Differences in Presentation, Risk Factors, Drug and Interventional Therapies, and Outcomes of Elderly Patients with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.	1.7	3
195	A propósito de: ¿Puede reducir la mortalidad de los pacientes con EPOC la profilaxis domiciliar de la enfermedad tromboembólica venosa? <i>Archivos De Bronconeumología</i> , 2007, 43, 523-524.	0.8	2
196	Early discharge and outpatient treatment of patients admitted for acute pulmonary embolism. <i>European Respiratory Journal</i> , 2013, 41, 487-488.	6.7	2
197	Outpatient Management Eligibility Criteria for Patients Who Have Acute Symptomatic Pulmonary Embolism. <i>Annals of the American Thoracic Society</i> , 2015, 12, 623-624.	3.2	2
198	Cardiopulmonary exercise testing with ventilatory gas analysis for evaluation of chronic thromboembolic pulmonary hypertension: Unmasking its role after a therapeutic intervention. <i>International Journal of Cardiology</i> , 2019, 296, 155-156.	1.7	2

#	ARTICLE	IF	CITATIONS
199	Hemopericardium and Cardiac Tamponade as a Complication of Vena Caval Filters: Systematic Review of the Published Literature and the MAUDE Database. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984911.	1.7	2
200	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , 2020, 186, 78-79.	1.7	2
201	Safety of Apixaban for Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 547-551.	3.4	2
202	Imaging modalities for confirming pulmonary embolism during pregnancy: results from a multicenter international study. <i>European Radiology</i> , 2022, 32, 1238-1246.	4.5	2
203	Sex-differences in the effect of obstructive sleep apnea on patients hospitalized with pulmonary embolism and on in-hospital mortality. <i>Scientific Reports</i> , 2021, 11, 18390.	3.3	2
204	Implications of Abnormal Troponin Levels With Normal Right Ventricular Function in Normotensive Patients With Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096776.	1.7	2
205	Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism. <i>Blood</i> , 2019, 134, 2429-2429.	1.4	2
206	Association between obstructive sleep apnea and venous thromboembolism recurrence: results from a French cohort. <i>Thrombosis Journal</i> , 2022, 20, 1.	2.1	2
207	Response. <i>Chest</i> , 2022, 161, e131-e132.	0.8	2
208	Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial. <i>Thrombosis Journal</i> , 2022, 20, 10.	2.1	2
209	Ibero-American Society of Interventionism (SIDI) and the Spanish Society of Vascular and Interventional Radiology (SERVEI) Standard of Practice (SOP) for the Management of Inferior Vena Cava Filters in the Treatment of Acute Venous Thromboembolism. <i>Journal of Clinical Medicine</i> , 2022, 11, 77.	2.4	2
210	Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 872115.	2.4	2
211	Prognostication of Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1096-1097.	5.6	1
212	Response. <i>Chest</i> , 2017, 151, 728-729.	0.8	1
213	Características clínicas y pronóstico de la tromboembolia pulmonar secundaria al síndrome de clase turista. <i>Archivos De Bronconeumología</i> , 2017, 53, 495-500.	0.8	1
214	Surrogate Endpoints for Pulmonary Hypertension Management and Trial Design. <i>Journal of the American College of Cardiology</i> , 2018, 71, 764-765.	2.8	1
215	Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos. <i>Archivos De Bronconeumología</i> , 2018, 54, 359-360.	0.8	1
216	Clinical gestalt versus prognostic scores for prognostication of patients with acute symptomatic pulmonary embolism. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 136-140.	0.2	1

#	ARTICLE	IF	CITATIONS
217	Scores to Identify Occult Cancer in Venous Thromboembolism: Do They Work?. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1343-1344.	3.4	1
218	The Role of the Pulmonologist in a Pulmonary Embolism Response Team (PERT): A Time to Come on Stage. <i>Archivos De Bronconeumologia</i> , 2019, 55, 1-2.	0.8	1
219	Assembly 13: placing the pulmonary circulation in the heart of ERS. <i>Breathe</i> , 2019, 15, 88-89.	1.3	1
220	The Role of the Pulmonologist in a Pulmonary Embolism Response Team (PERT): A Time to Come on Stage. <i>Archivos De Bronconeumologia</i> , 2019, 55, 1-2.	0.8	1
221	Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093120.	1.7	1
222	Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism. <i>The Cochrane Library</i> , 0, , .	2.8	1
223	Refinement of a modified simplified Pulmonary Embolism Severity Index for elderly patients with acute pulmonary embolism. <i>International Journal of Cardiology</i> , 2021, 335, 111-117.	1.7	1
224	Respuesta a "Consenso multidisciplinar, ¿falta alguien?". <i>Archivos De Bronconeumologia</i> , 2021, 57, 612.	0.8	1
225	Participación de los equipos de respuesta rápida de tromboembolia pulmonar durante el perioperatorio. <i>Archivos De Cardiología De Mexico</i> , 2020, 90, 321-327.	0.2	1
226	Comparison of Full-Dose vs Moderate-Dose Systemic Thrombolysis for the Treatment of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2022, 162, 448-451.	0.8	1
227	A Comparison of GFR Calculated by Cockcroft-Gault vs. MDRD Formula in the Prognostic Assessment of Patients with Acute Pulmonary Embolism. <i>Disease Markers</i> , 2021, 2021, 1-9.	1.3	1
228	[Translated article] Prognostic Significance of Findings on CTPA Supporting an Alternative Diagnosis to PE Among Patients Hospitalized for an Exacerbation of COPD: Predefined Subanalysis of the SLICE Trial. <i>Archivos De Bronconeumologia</i> , 2022, 58, T412-T417.	0.8	1
229	The $\hat{\mu} \pm$ -Encoders for Robust A/D Conversion. <i>Acta Applicandae Mathematicae</i> , 2009, 107, 313-323.	1.0	0
230	Mortality-Risk Profiling using Doppler Leg Scans in Patients with Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 856-857.	5.6	0
231	Rebuttal From Dr Jiméñez. <i>Chest</i> , 2013, 143, 302-303.	0.8	0
232	Prognostic Scores in Pulmonary Embolism: Response. <i>Chest</i> , 2013, 143, 873.	0.8	0
233	Hipertensión pulmonar tromboembólica crónica: la experiencia mejora los resultados. <i>Archivos De Bronconeumologia</i> , 2014, 50, 507-508.	0.8	0
234	National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism: An Update. <i>Archivos De Bronconeumologia</i> , 2016, 52, 61-62.	0.8	0

#	ARTICLE	IF	CITATIONS
235	The Reply. American Journal of Medicine, 2017, 130, e271.	1.5	0
236	Venous Thromboembolic Disease and Cancer: A Challenge for Clinicians. Archivos De Bronconeumologia, 2018, 54, 359-360.	0.8	0
237	Highlights from the ERS International Congress 2018: Assembly 13 " Pulmonary Vascular Diseases. ERJ Open Research, 2019, 5, 00202-2018.	2.6	0
238	Duración de la anticoagulación tras una tromboembolia de pulmón: una decisión no siempre sencilla. Archivos De Bronconeumologia, 2020, 56, 617-618.	0.8	0
239	Response. Chest, 2021, 159, 2513.	0.8	0
240	Multidisciplinary consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, 2021, , .	0.8	0
241	Spanish consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, 2021, 57, 612.	0.8	0
242	Cardiovascular mortality and morbidity in pulmonary embolism. , 2020, , 184-197.		0
243	A Pulmonary Embolism Diagnostic Strategy in Patients Hospitalized for COPD Exacerbation"Reply. JAMA - Journal of the American Medical Association, 2022, 327, 184.	7.4	0
244	Clinical characteristics and course in emergency department patients with chronic obstructive pulmonary disease and symptomatic acute venous thromboembolic disease: secondary analysis of the ESPHERIA registry. Emergencias, 2020, 32, 40-44.	0.6	0
245	Profiles of patients with venous thromboembolic disease in the emergency department and their medium-term prognosis: data from the ESPHERIA registry. Emergencias, 2021, 33, 107-114.	0.6	0
246	Major bleeding in patients with pulmonary embolism presenting with syncope. European Journal of Clinical Investigation, 2022, , e13774.	3.4	0
247	Significado pronóstico de los diagnósticos alternativos a la TEP hallados en la tomografía computarizada de tórax de pacientes ingresados por agudización de EPOC: subanálisis predefinido del ensayo SLICE. Archivos De Bronconeumologia, 2022, , .	0.8	0
248	Rebuttal From Dr David Jimenez et Al. Chest, 2022, 161, 1453-1455.	0.8	0